Compare Cytokinetics Inc (CYTK) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Manulife Financial Corporation — how do they compare? Cytokinetics Inc trades at $81.52 (market cap $11.12B), while Manulife Financial Corporation trades at $42.24 (market cap $68.68B). The key difference: Manulife Financial Corporation is far larger — about 6.2× Cytokinetics Inc's market cap, and Manulife Financial Corporation pays a 3.2% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MFC | |
|---|---|---|
Market Cap | $11.12B | $68.68B |
Sector | Technology | Financials |
52-Week High | $87.26 | $41.69 |
52-Week Low | $33.23 | $29.90 |
Enterprise Value | $11.59B | $65.24B |
Dividend Yield | — | 3.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Manulife Financial (MFC) trades at $41.29, unchanged on the day, near its 52-week high. The stock shows a bullish technical signal with strong moving averages, while fundamentals reveal steady revenue growth to $53.01B in 2025 and a net income margin of 12.07%. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with 57% buy ratings. Key developments include a dividend payment and AI partnership expansions.
Outlook is cautiously optimistic with growth driven by Asia operations and AI initiatives, but risks include Q1 earnings miss and regulatory scrutiny. Valuation at P/E 16.89 and P/B 2.17 appears reasonable. Investors should monitor execution on earnings recovery and wealth management flows amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
